Literature DB >> 28272018

Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.

Lana Ganoci, Tamara Božina, Nikica Mirošević Skvrce, Mila Lovrić, Petar Mas, Nada Božina.   

Abstract

BACKGROUND: Data on the frequency of pharmacogenetic polymorphisms in the Croatian population are limited. We determined and analyzed frequencies for the most important CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genetic variants in the Croatian population.
METHODS: 2637 subjects were included. Genotyping was performed by real-time polymerase chain reaction (PCR) using TaqMan® DME or TaqMan® SNP Genotyping Assays, and by PCR, and PCR-RFLP analysis.
RESULTS: For CYP2C9, allele frequencies of *2 and *3 variant were 14.5% and 7.6%, respectively. Among them, 3.98% of subjects were predicted to be poor metabolizers. For CYP2C19, the most frequent variant alleles were *2 (14.8%), and *17 (23.7%), while 2.4% of subjects were predicted to be poor metabolizers, and 5.39% were homozygous carriers of *17 predicted to be ultrarapid metabolizers (UM). For CYP2D6, the frequencies of tested variant alleles were *3 (2.2%), *4 (17.4%), *5 (1%), *6 (1.1%), and *41 (10.8%). Out of these, 5.59% were predicted to be poor metabolizers, 3.19% were classified as UM while 1.0% were carriers of variant alleles duplications (undefined phenotype). For CYP3A4 allele frequencies of *1B and *22 variants were 1.4% and 2.7%, respectively. Allele frequency of CYP3A5*3 was 95.5%. Analyzing CYP3A cluster according to the combination of CYP3A4*22 and CYP3A5*3 revealed 5.34% of subjects to be poor metabolizers, while 8.66% were classified as extensive metabolizers.
CONCLUSIONS: The frequency of the CYP allelic variants, genotypes, and predicted phenotypes in the Croatian population is in accordance with the other European populations, between the values of published data for Middle European and Mediterranean populations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28272018     DOI: 10.1515/dmpt-2016-0024

Source DB:  PubMed          Journal:  Drug Metab Pers Ther        ISSN: 2363-8915


  11 in total

1.  Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.

Authors:  Iva Klarica Domjanović; Mila Lovrić; Vladimir Trkulja; Željka Petelin-Gadže; Lana Ganoci; Ivana Čajić; Nada Božina
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

2.  Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.

Authors:  Ivan Skadrić; Oliver Stojković
Journal:  Int J Legal Med       Date:  2019-12-20       Impact factor: 2.686

3.  High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness.

Authors:  L Bernal-Martínez; L Alcazar Fuoli; B Miguel-Revilla; A Carvalho; M S Cuétara Garcia; J Garcia-Rodriguez; C Cunha; E Gómez-García de la Pedrosa; A Gomez-Lopez
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.

Authors:  Iveta Merćep; Ivana Radman; Vladimir Trkulja; Tamara Božina; Livija Šimičević; Ema Budimir; Lana Ganoci; Nada Božina
Journal:  Eur J Clin Pharmacol       Date:  2021-10-19       Impact factor: 2.953

5.  Pharmacogenetic distinction of the Croatian population from the European average.

Authors:  Željka Celinšćak; Matea Zajc Petranović; Maja Šetinc; Anita Stojanović Marković; Marijana Peričić Salihović; Hrvojka Marija Zeljko; Branka Janićijević; Nina Smolej Narančić; Tatjana Škarić-Jurić
Journal:  Croat Med J       Date:  2022-04-30       Impact factor: 2.415

6.  Different Pharmacokinetics of Tramadol, O-Demethyltramadol and N-Demethyltramadol in Postoperative Surgical Patients From Those Observed in Medical Patients.

Authors:  Nenad Neskovic; Dario Mandic; Saska Marczi; Sonja Skiljic; Gordana Kristek; Hrvoje Vinkovic; Boris Mraovic; Zeljko Debeljak; Slavica Kvolik
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

7.  Clinical Relevance of CYP2D6 Polymorphisms in Patients of an Austrian Medical Practice: A Family Practice-Based Observational Study.

Authors:  Gustav Kamenski; Seda Ayazseven; Anne Berndt; Waltraud Fink; Lukas Kamenski; Sonja Zehetmayer; Helene Pühringer
Journal:  Drugs Real World Outcomes       Date:  2020-03

Review 8.  Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.

Authors:  Nada Božina; Majda Vrkić Kirhmajer; Livija Šimičević; Lana Ganoci; Nikica Mirošević Skvrce; Iva Klarica Domjanović; Iveta Merćep
Journal:  Croat Med J       Date:  2020-04-30       Impact factor: 1.351

9.  Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina.

Authors:  Stojko Vidović; Ranko Škrbić; Miloš P Stojiljković; Vanja Vidović; Jelena Bećarević; Svjetlana Stoisavljević-Šatara; Nela Maksimović
Journal:  Arh Hig Rada Toksikol       Date:  2021-06-28       Impact factor: 2.078

Review 10.  Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes.

Authors:  Jochen Fracowiak; Tatjana Huebner; Steffen Heß; Christoph Roethlein; Daria Langner; Udo Schneider; Felix Falkenberg; Catharina Scholl; Roland Linder; Julia Stingl; Britta Haenisch; Michael Steffens
Journal:  Pharmacogenomics J       Date:  2022-01-31       Impact factor: 3.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.